Previous 10 | Next 10 |
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib are encouraging and continue to improve over prior reporting The ORR of 89% and CR rate of 43% for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to the historical ORR of ...
Oncternal Therapeutics, Inc. (ONCT) Q3 2022 Earnings Conference Call November 03, 2022, 05:00 PM ET Company Participants Rich Vincent - Chief Financial Officer Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call ...
Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q3 GAAP EPS of -$0.21 (vs. -$0.19 Y/Y) beats by $0.03 . Revenue of $0.38M (-81.9% Y/Y) beats by $0.13M . For further details see: Oncternal Therapeutics GAAP EPS of -$0.21 beats by $0.03, revenue of $...
Initiated Phase 3 global registrational Study ZILO-301 of our zilovertamab product candidate targeting ROR1 in combination with ibrutinib for the treatment of patients with MCL Received acceptance for an oral presentation at the 64 th ASH Annual Meeting and Exposit...
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presente...
Oncternal Therapeutics ( NASDAQ: ONCT ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, after market close. The consensus EPS Estimate is -$0.23 (-21.1% Y/Y) and the consensus Revenue Estimate is $0.25M (-88.1% Y/Y). Over the last 3 months, EPS ...
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2022 financial results after the U.S. financial mark...
Clinical-stage biopharma Oncternal Therapeutics ( NASDAQ: ONCT ) on Monday said the U.S. FDA had cleared it to proceed with a phase 1/2 dose escalation study of its car T-cell therapy ONCT-808 for the treatment of aggressive B cell non-Hodgkin’s lymphoma ((B NHL)). ...
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a ‘Study May Proceed’ letter from the U.S. Food and Drug ...
Oncternal Therapeutics ( NASDAQ: ONCT ) said on Tuesday it had begun a Phase 3 global registrational study of zilovertamab (ZILO-301) to treat patients with relapsed/refractory mantle cell lymphoma. The Company received its first Institutional Review Board approval for...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer ...